Search
Displaying 451–460 of 624 for “retinal diseases”
-
DHA and EPA for Stargardt Disease — an Evolving Story
Research NewsThese healthy fats have exciting potential for treating a wide range of retinal degenerations and other health conditions.
-
Tempering the Immune System to Save Vision
Research NewsGreat progress is being made in identifying targets for therapies, including using the body’s own protective systems to keep the photoreceptors alive.
-
Eva Lou Schroeder Watson's Enduring Legacy
Beacon StoriesEva Watson’s life was marked by her dedication to advancing medical research for blinding diseases, and her generous bequest to the Foundation Fighting Blindness ensures her advocacy will endure. Her story highlights the profound impact of her contributions to driving treatments and cures for blinding diseases.
-
Antabuse Moves into Clinical Trial for People with RP
Research NewsResearchers believe the FDA-approved drug can reduce the hyperactivity of ganglion cells to improve vision.
-
Research News
No serious adverse events were reported. One patient had encouraging improvement in retinal sensitivity.
-
Eye on the Cure Podcast | Episode 61: Dr. Jose Sahel
Eye on the CureDr. Jose Sahel, one of the most honored and accomplished leaders in the retinal disease research space, talks with host Ben Shaberman about his establishment and leadership of renowned ophthalmology clinical research centers at the University of Pittsburgh Medical Center and Institut de la Vision in Paris. They also discuss emerging inherited retinal disease therapies from SparingVision, a biotech co-founded by Dr. Sahel.
-
Eye on the Cure Podcast | Episode 58: Jason Comander
Eye on the CureJason Comander, Md, PhD, clinical researcher, surgeon, and director of the Inherited Retinal Disease Disorders Service at Mass Eye and Ear, talks to host Ben Shaberman about his administration of LUXTURNA gene therapy to RPE65 patients, his team’s re-analysis of vitamin A therapy for retinitis pigmentosa, and passion for retinal research and patient care.
-
Atsena’s LCA-GUCY2D Gene Therapy Improves Vision in Phase 1/2 Clinical Trial
Research NewsThe company is planning to move the emerging treatment into a pivotal trial
-
Endogena Launches Clinical Trial of Therapy to Activate Stem Cells in RP Patients’ Retinas
Research NewsThe emerging treatment is gene-agnostic.
-
ProQR Doses First Patients in Phase 2/3 Clinical Trials for its USH2A-Exon 13 RNA Therapy
Research NewsThe Sirius trial is for USH2A (exon 13 mutations) patients with advanced vision loss. The Celeste trial is for USH2A (exon 13 mutations) patients with moderate to early vision loss.
.png)
.png)
.png)
